Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

Also called NCT06317805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
AOP Orphan Pharmaceuticals AG (from the registry)
Registry
  • NCT NCT06317805
  • EU CT 2023-504351-26-01
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Argentina, Austria, Czechia, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Uruguay (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06317805. Randomized; no masking; primary purpose treatment. Start 2023-12-06 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Acronym
TripleTRE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Generic treprostinil sodium + Standard of Care (Double Oral)
Intervention (Drug)
Standard of Care - Double Oral
Lead sponsor
AOP Orphan Pharmaceuticals AG (class: industry)
Collaborator
ANOVA CRO s.r.o. (class: not stated)
Collaborator
PharmaLex Belgium (class: not stated)
Collaborator
Aixial s.r.o. (class: not stated)
Collaborator
GCP-Service International Ltd. & Co. KG (class: industry)

Record details

Record id
cardio:ct-nct06317805
Content hash
73d3fb4712de185d62e8cfedefe3946277ed654ae8a09d5cd2b101b48e38cee1